Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Cystic Fibrosis, Homozygous for the F508del CFTR Mutation”

33 trials

Showing 20 of 33 results

Large-scale testing (Phase 3)Study completedNCT01897233
What this trial is testing

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 62
Large-scale testing (Phase 3)Study completedNCT01807923
What this trial is testing

Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Vertex Pharmaceuticals Incorporated 559
Testing effectiveness (Phase 2)Study completedNCT02709109
What this trial is testing

Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Parion Sciences 147
Post-approval studies (Phase 4)Ended earlyNCT02823470
What this trial is testing

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 24
Early research (Phase 1)Study completedNCT03093714
What this trial is testing

Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

Who this might be right for
Cystic Fibrosis
Flatley Discovery Lab LLC 27
Large-scale testing (Phase 3)Study completedNCT01931839
What this trial is testing

Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Vertex Pharmaceuticals Incorporated 1,164
Testing effectiveness (Phase 2)Study completedNCT02589236
What this trial is testing

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Nivalis Therapeutics, Inc. 138
Post-approval studies (Phase 4)Study completedNCT02875366
What this trial is testing

The Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 70
Testing effectiveness (Phase 2)Study completedNCT02070744
What this trial is testing

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 40
Testing effectiveness (Phase 2)Study completedNCT01225211
What this trial is testing

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 312
Large-scale testing (Phase 3)Study completedNCT03559062
What this trial is testing

Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 67
Early research (Phase 1)Study completedNCT01746784
What this trial is testing

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Nivalis Therapeutics, Inc. 66
Testing effectiveness (Phase 2)Study completedNCT02730208
What this trial is testing

Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 41
Large-scale testing (Phase 3)Study completedNCT02390219
What this trial is testing

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

Who this might be right for
Cystic FibrosisAdvanced Lung Disease
Vertex Pharmaceuticals Incorporated 46
Large-scale testing (Phase 3)Study completedNCT02953314
What this trial is testing

Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 83
Large-scale testing (Phase 3)Study completedNCT05076149
What this trial is testing

VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 597
Testing effectiveness (Phase 2)Ended earlyNCT00953706
What this trial is testing

Study of Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 140
Large-scale testing (Phase 3)Study completedNCT02347657
What this trial is testing

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VX-661 in Combination With Ivacaftor

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 510
Large-scale testing (Phase 3)Study completedNCT02325362
What this trial is testing

Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the F508del Mutation

Who this might be right for
Cystic Fibrosis
Assistance Publique - Hôpitaux de Paris 16
Large-scale testing (Phase 3)Study completedNCT02565914
What this trial is testing

Evaluate the Safety and Efficacy of Long Term Treatment With VX-661 in Combination With Ivacaftor in Participants With Cystic Fibrosis Who Have an F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 1,131
Next Page

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation